Agilent Technologies and Roche Establish Agreement to Provide Continued Service and Support to Roche NimbleGen Microarray Customers
Agilent Technologies Inc. (NYSE: A) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services.
(Media-Newswire.com) - SANTA CLARA, Calif., and PENZBERG, Germany, Nov. 7, 2012
Agilent Technologies Inc. ( NYSE: A ) and Roche ( SIX: RO, ROG; OTCQX: RHHBY ) today announced the signing of an exclusive agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services.
Researchers using NimbleGen microarrays for all applications, including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation and gene expression can transition to Agilent arrays, effective immediately, with minimal disruption. The similarities of the technologies and products from both companies provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.
"This global collaboration provides our customers with a confident and straightforward solution to move from NimbleGen to Agilent microarrays," said Dan Zabrowski, head of Roche Applied Science.
"With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect."
"We are working closely with Roche to help customers make the transition to Agilent microarray products," said Robert Schueren, vice president and general manager of Agilent's Genomics Systems Division. "Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond. Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment."
For more information about the transition, visit www.agilent.com/genomics/microarrays. For questions relating to service and support of NimbleGen microarray products, call 1-800-227-9770, or email firstname.lastname@example.org.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
-------------------------------------------------------------------------------- About Agilent Technologies Agilent Technologies Inc. ( NYSE: A ) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,000 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.
# # #
Susan Berg +1 408 553 7093 email@example.com
Dr. Claudia Schmitt +49 8856 60 10210 firstname.lastname@example.org
This story was released on 2012-11-12. Please make sure to visit the official company or organization web site to learn more about the original release date. See our disclaimer for additional information.